BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Al-Dorra Holdings to IPO New Pharmaceutical Subsidiary, Hail First Pharma Inc.


1/21/2011 7:00:57 AM

KUWAIT--(Marketwire - 01/20/11) - Al-Dorra Holdings, a privately held Kuwaiti company, announced today the intent to IPO its newly formed subsidiary Hail First Pharma Inc. in the first quarter of this year.

According to the company, Hail First Pharma Inc. is the result of several acquisitions and or joint-ventures with international pharmaceutical companies including but not limited to Spencer Pharmaceutical Inc., a public traded company listed on the US OTC Markets (Pinksheets:SPPH - News). Hail First Pharma is poised to become the leading pharmaceutical of the Middle East with plans on developing a state-of-the-art research center in the Prince Abdulaziz bin Mousaed Economic City in the Northern province of Hail Saudi Arabia.

"The acquisitions, joint-venture as well as the financial participation from various regional and international partners will make this IPO a tremendous success," said Hussain Al-Awaid, President of Al-Dorra. "The recently announced acquisition of Spencer Pharmaceutical will provide a platform for development and enable us to immediate market a diabetic drug to the region desperately in need," further added Mr. Al-Awaid.

Important Information

About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.

Contact: Hussain Al-Awaid Tel +971-5061-25585

Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES